Product Pipeline

Future Products

CYBIS 10:25

Pharmaceutical

  • Chronic Pain Formulation
  • THC + CBD + compounds
  • Clinical Development Programme
  • Administration: Oral solution
  • Full spectrum
  • Patient target: 2nd line therapy for chronic non cancer pain.

CYM-001

Pharmaceutical

  • Anxiety Formulation
  • CBD + specific formulated compounds
  • International ARTG registration and export
  • Administration: Oral solution
  • Full spectrum
  • Patient target: Highly Anxiolytic patients 

CYM-004

Pharmaceutical
(no THC)

  • Anxiety Formulation
  • CBD + specific formulated compounds
  • International ARTG registration and export
  • Administration: Oral solution
  • Full spectrum
  • Patient target: Highly Anxiolytic patients
cymra-icon

Cymra’s Pharmaceutical Experience and IP in regards to product and formulation development, clinical programs and regulatory pathways provides us a unique advantage over non pharmaceutical companies.

Note: All dates and products are provided as an estimate, supply times and products may vary.

Medical Cannabis Information and Updates

Want to keep up to date with the latest Medical Cannabis Information in Australia and from around the world? We will send you informative information from time to time so you can learn about cannabis and if it can help you.

Company

Patients

Healthcare Professionals

Genetic Services

Quick Links

© 2021 Cymra Life Sciences   – ABN 54 621 123 760

Medical Cannabis Information and Updates

Want to keep up to date with the latest Medical Cannabis Information in Australia and from around the world? We will send you informative information from time to time so you can learn about cannabis and if it can help you.